Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

Androgen receptor (AR) is a steroid receptor transcriptional factor for testosterone and
dihydrotestosterone consisting of four main domains, the N-terminal domain, DNA-binding …

Many effective drugs for metastatic and/or advanced-stage cancers have been developed
over the past decade, although the evolution of resistance remains the major barrier to …

Background The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-
binding domain, which is the target of enzalutamide and abiraterone, but remains …

The androgen-signaling axis plays a pivotal role in the pathogenesis of prostate cancer.
Since the landmark discovery by Huggins and Hodges, gonadal depletion of androgens has …

Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …

Importance We previously showed that detection of androgen receptor splice variant 7 (AR-
V7) in circulating tumor cells (CTCs) from men with castration-resistant prostate cancer …

The treatment of advanced prostate cancer has been transformed by novel antiandrogen
therapies such as enzalutamide. Here, we identify induction of glucocorticoid receptor (GR) …

Current treatments for castration-resistant prostate cancer (CRPC) that target androgen
receptor (AR) signaling improve patient survival, yet ultimately fail. Here, we provide novel …

Activation of androgen receptor (AR) is crucial for prostate cancer growth. Remarkably, also
castration-resistant prostate cancer (CRPC) is dependent on functional AR and several …